Bausch + Lomb Corp logo

Bausch + Lomb Corp(BLCO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 15 days
PROFIT SINCE LAST BUY
+2.7% ▲
LAST CLOSE
$20.95
11/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BLCO

11/18/2026: BLCO (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Bausch + Lomb Corp is a major global eye health company providing a diversified portfolio of contact lenses, consumer eye care products, ophthalmic pharmaceuticals, and surgical equipment. Its main business strengths include a century-old trusted brand legacy, a broad multi-segment product footprint, and steady top-line revenue growth. The primary investment story centers on expanding high-margin silicone hydrogel contact lenses and advancing specialty pharmaceutical pipelines for conditions like dry eye. However, the company faces intense competition from larger profitable peers, a heavy debt load, and historical challenges in translating strong sales into consistent net profitability. The stock suits growth-oriented or momentum investors willing to monitor execution milestones, though conservative dividend seekers should note the absence of cash payouts.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile top-line revenue growth is steady, inconsistent net profitability makes it a mixed choice for pure growth seekers.
Momentum investorStrong fit while signal remains positivePositive quarterly guidance lifts and product milestone updates can trigger sharp upward price momentum.
Value investorMixed fitThe stock trades at reasonable earnings multiples, but bottom-line losses require careful fundamental evaluation.
Dividend investorWeak fitBausch + Lomb does not currently pay a dividend, making it unsuitable for income-focused portfolios.
Low-risk investorWeak fitDebt leverage, volatile earnings, and intense sector competition generate too much risk for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock frequently reacts sharply to earnings reports, regulatory updates, and guidance adjustments.
Valuation riskMediumValuation multiples remain sensitive to whether management can successfully expand operating margins over time.
Competition risk (Alcon and Cooper Companies)HighStiff competition from larger, highly profitable peers can pressure market share and pricing power.
Business qualityMediumStrong brand recognition and high gross margins are tempered by elevated SG&A expenses and historical net losses.
Dividend incomeLow / noneThe company distributes no dividend payouts to shareholders.
Execution riskMedium / highSuccessfully integrating major product acquisitions like XIIDRA and scaling pipeline treatments is critical for financial turnaround.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 7.50B USD
Price to earnings Ratio -
1Y Target Price 21.93
Price to earnings Ratio -
1Y Target Price 21.93
Volume (30-day avg) 963.5K shares
Beta 0.52
52 Weeks Range 14.44 - 21.40
Updated Date 11/18/2026
52 Weeks Range 14.44 - 21.40
Updated Date 11/18/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.32

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.0%
Active BUY / eligible
67 / 108
30-Day BUY Count Change
+22
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
50.0%
Active BUY / eligible
3 / 6
30-Day BUY Count Change
+1

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -24.3%
Avg. Invested days 45
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/18/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BLCO receives a 3-star rating based on the available scored pillars. The rating is constrained by weak unit economics, weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
BLCO has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-13.6%), weak cash generation (FCF margin -1.3%), moderate revenue growth (+6.5%).

Financial Health Rating

★★★★★
BLCO's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 51.1% of revenue). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is BLCO's strongest growth driver at +6.5% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while earnings growth (-13.6%, negative) and free-cash-flow growth (-11.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 11.7% (soft) and 13.0% of outstanding shares are publicly tradable (soft). Insider ownership of 87.12% supports management-shareholder alignment.

Top 5 Institutional Investors

ICAHN CARL C 0.98%
Oaktree Capital Management LLC 0.96%
Deutsche Bank AG 0.96%
D. E. Shaw & Co LP 0.93%
Davidson Kempner Capital Management LP 0.88%

Unit Economics (Per $1K Revenue)

★★★★★
BLCO generates approximately $548 of gross profit, $37 of operating income, and $-13 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Negative free cash flow explains the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -11.04% (Tax Credit)

Quantitative Style Profile

★★★★★
BLCO has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Vision CareContact lenses (such as INFUSE and Ultra) and consumer eye care products (like Biotrue solutions and Ocuvite vitamins).This is the largest segment, driven by everyday consumer purchases and recurring contact lens usage.
PharmaceuticalsPrescription and generic eye drops and therapies addressing dry eye, glaucoma, and inflammation (such as XIIDRA and Vyzulta).Provides higher-margin specialty medical products prescribed by eye care specialists.
SurgicalCataract equipment, intraocular lenses (IOLs), vitreoretinal surgical tools, and consumables.Supplies hospital operating rooms and surgical centers with advanced equipment and procedural hardware.
Geographic OperationsCommercial sales spanning the United States, Europe, Asia, and international markets.Global diversification buffers the company against localized economic downturns.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-28
When Before Market
Estimate 0.21
Actual 0.34

Profitability

Profit Margin -2.05%
Operating Margin (TTM) 9.41%

Management Effectiveness

Return on Assets (TTM) 2.29%
Return on Equity (TTM) -1.58%

Valuation

Trailing PE -
Forward PE 18.15
Enterprise Value 12.11B
Price to Sales(TTM) 1.38
Enterprise Value 12.11B
Price to Sales(TTM) 1.38
Enterprise Value to Revenue 2.23
Enterprise Value to EBITDA 15.42
Shares Outstanding 357.50M
Shares Floating 46.39M
Shares Outstanding 357.50M
Shares Floating 46.39M
Percent Insiders 87.12
Percent Institutions 11.74

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.